HCW Biologics, WY Biotech in License Agreement for Immunotherapeutic Product Candidate

 HCW Biologics entered into License, Research and Co-Development Agreement

with WY Biotech for one of its new proprietary preclinical molecules

HCW Biologics to receive upfront payment of $7 million and is eligible to receive additional milestone payments and double-digit royalties on future product sales

https://www.globenewswire.com/news-release/2024/11/18/2982613/0/en/HCW-Biologics-and-WY-Biotech-Announce-License-Agreement-for-Immunotherapeutic-Product-Candidate.html